View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
February 19, 2021

Altasciences completes acquisition of US-based CRO WCCT Global

Mid-size CRO/CDMO Altasciences has acquired early-stage clinical research organisation (CRO) WCCT Global.

Mid-size CRO/CDMO Altasciences has acquired early-stage clinical research organisation (CRO) WCCT Global.

Free Report
img

What is the Global Healthcare and Pharma Market Q2 Outlook?

Given the background of high inflation, re-emerging supply chain issues, and the widespread macro-economic implications of the Ukraine conflict, the global pharmaceutical industry is facing an entirely new set of challenges following the turbulence of the COVID-19 pandemic. GlobalData’s World Markets Healthcare (WMH) service has released its latest Q2 forecast. This report incorporates the latest thinking on the opportunities and risks this new environment presents for pharma companies. However, the pharma sector is proving resilient, and we are projecting 4.4% global growth for the year ahead. Yet it remains that the current economic picture is inverting some baseline assumptions from previous quarterly forecasts and altering which markets we expect the key growth levers to derive from. Download our latest executive summary for a snapshot view of what our clients use to formulate winning strategies.
by GlobalData
Enter your details here to receive your free Report.

WCCT is located in southern California on the US West Coast.

Altasciences noted that the acquisition will complement its current clinical operations in Montreal, Canada, and Kansas City, US.

WCCT’s facility lies within close access to Altasciences’ preclinical facility in the state of Washington.

Altasciences co-chief operating officer Steve Mason said: “This acquisition expands Altasciences’ footprint by providing Phase I and II clinical pharmacology services on the West Coast, and adds 180 beds to our current 400-bed offering.

“Furthermore, it allows us to enhance our capabilities with expertise in ethnobridging and other speciality areas for hard-to-recruit study populations.”

The acquisition was completed on 12 February.

Altasciences CEO Chris Perkin said: “This acquisition is an integral part of Altasciences’ strategic growth plan to provide a comprehensive, fully integrated early phase drug development solution to address the ever-changing outsourcing challenges of biopharmaceutical companies across the globe.”

Founded in 1998, WCCT Global has conducted more than 600 Phase I studies in its area of expertise, out of about 1,000 Phase I-IV studies the company has conducted so far.

WCCT Global executive chairman Gregory Hanson said: “Joining the Altasciences team will enhance our offering while allowing us to continue the responsive delivery of quality research data to our global biopharmaceutical clients.”

Related Companies

Free Report
img

What is the Global Healthcare and Pharma Market Q2 Outlook?

Given the background of high inflation, re-emerging supply chain issues, and the widespread macro-economic implications of the Ukraine conflict, the global pharmaceutical industry is facing an entirely new set of challenges following the turbulence of the COVID-19 pandemic. GlobalData’s World Markets Healthcare (WMH) service has released its latest Q2 forecast. This report incorporates the latest thinking on the opportunities and risks this new environment presents for pharma companies. However, the pharma sector is proving resilient, and we are projecting 4.4% global growth for the year ahead. Yet it remains that the current economic picture is inverting some baseline assumptions from previous quarterly forecasts and altering which markets we expect the key growth levers to derive from. Download our latest executive summary for a snapshot view of what our clients use to formulate winning strategies.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena